Background Long term administration of oral corticosteroids in patients with asthma may be associated with serious side effects. Non-steroidal anti-inflammatory drugs, including gold salts, have been shown to reduce the need for systemic corticosteroid treatment in uncontrolled studies. The effect of oral gold (auranofin) on asthma symptoms, lung function, and the need for oral prednisone treatment was investigated. Methods A 26 week randomised, double blind, placebo controlled, parallel group trial of auranofin was performed in 32 patients with moderately severe chronic asthma who required an oral corticosteroid dose of at least 5 mg prednisone a day (or equivalent) or 2 5 mg/day prednisone plus more than 800 _g/day inhaled corticosteroids. Auranofin was given orally in a dose of 3 mg twice daily.
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Asthma symptoms, lung function, and adverse effects were assessed at regular intervals. After 12 weeks of treatment prednisone dosage was tapered down by 2 5 mg every two weeks if the patient was clinically stable. Asthma exacerbations were treated with short courses of high doses of oral steroids. Results Twenty eight of the 32 patients, 13 in the placebo group and 15 in the auranofin group, completed the study.
The total corticosteroid reduction achieved after 26 weeks of treatment was significantly greater (4 mg) in the auranofin group than in the placebo group (0-3 mg). The number of exacerbations requiring an increase of steroids was greater in the placebo group (2-1) than in the active group (0-9). A significant increase in FEV1 of 6-4% predicted occurred in the auranofin group during the study and there was a reduction of asthma symptoms such as wheezing and cough. There was no difference between the groups in peak flow measurements or in the number of asthma attacks. The incidence of side effects of auranofin was low, but exacerbations of constitutional eczema were noticeable.
Conclusion Auranofin provides an effective adjunct to treatment for steroid dependent asthma, leading to a reduction of oral steroid dose.
Airway inflammation plays a major part in the pathogenesis of bronchial hyperresponsiveness and asthma.'2 Topical drugs with antiinflammatory activity, such as inhaled corticosteroids, sodium cromoglycate, and nedocromil sodium, are being prescribed on a large scale to all types of asthmatic patients.34
These drugs improve asthma symptoms,57 prevent the increase in bronchial responsiveness after inhalation of allergen,8 and reduce bronchial hyperresponsiveness in allergic and non-allergic patients with asthma of mild to moderate severity.9 10 Some asthmatic patients, however, are refractory to even high doses of topical anti-inflammatory drugs and require systemic anti-inflammatory treatment. Oral and intravenous glucocorticosteroids are still considered the most effective treatment for severe asthma," but their long term administration may be associated with serious and sometimes irreversible side effects.'2 13 In some chronic inflammatory diseases, such as rheumatoid arthritis, other types of systemic anti-inflammatory drugs or steroid sparing agents,. including gold salts and methotrexate, have been used.1' Parenteral gold salts have been used to treat asthma for some time in Japan, with symptomatic improvement and a reduced need for corticosteroids." 6 Some evidence of a benefit from oral gold treatment was reported in two Anierican studies on patients with steroid dependent asthma,'7 18 a steroid sparing effect'718 and reduction in airway hyperresponsiveness to methacholine'8 being observed after 16-22 weeks of treatment. A comparative study of auranofin (oral gold) and parenteral gold has shown that the withdrawal rate due to adverse reactions was twice as high with parenteral gold. ' decrease in mean daytime or night-time peak flow of at least 10% over the previous seven days. At the end of the treatment period there was a final physical examination and laboratory test and a global assessment by the physician of the efficacy of the treatment.
ADVERSE REACTIONS
All adverse reactions observed by the investigator or reported by the patient were recorded. Haematological abnormalities were considered significant if there was a fall in the platelet count of more than 100 x 109/l or leucopenia (leucocytes < 3 0 x 109/1).
Repeated proteinuria (1+ proteinuria on more than one occasion) was considered to be a serious adverse reaction. When gastrointestinal symptoms such as diarrhoea occurred, the dose of auranofin was temporarily reduced to 3 mg daily for up to two weeks. The auranofin dose was increased to 3 mg twice daily once the symptoms had resolved. When eczema became worse a topical low grade corticosteroid ointment or an oral antihistamine drug (or both) was started. Patients with extensive persistent eczema resistant to treatment were withdrawn from the study.
STATISTICAL ANALYSIS
Differences between patients receiving auranofin and placebo were tested by the MannWhitney U test and the x2 test. Differences in changes over time between the auranofin and the placebo group were tested by repeated measures analysis of variance with week number as a covariate. As steroid use was irregular, change in steroid use with time was characterised by the Spearman rank correlation coefficient, calculated for each patient and averaged for the patients receiving auranofin and placebo.
As we had a sample of 13 subjects in each group and knew the standard deviation of the differences in daily prednisone dosage in the placebo group (5-2 mg), the power of the analysis was 0-8 (beta = 0-2) to detect a change greater than 50 mg prednisone/day when a = 0-05 (one tailed). in the auranofin group and decreased from 59-7 (19-45) to 50-2 (14-0) in the placebo group. The mean (SD) slopes of the regression lines between week number and FEV1 were significantly different between the two groups, being 0-25-(0-03) and -0-36 (0-13) respectively (p < 0-0001).
DIARY CARD ANALYSIS

Peakflow measurements
Daytime and night time peak flow measurements over time are shown in figure 3. There were no significant changes in daytime or night time peak flow measurements over time within the two groups (p > 0-94), nor were there significant differences in peak flow changes over time between the groups (daytime p > 0-19; night time p > 0-48).
Asthma symptoms
The number of days and nights per week with wheezing and the severity of coughing score during the day and during the night are shown in figure 4 . The mean number of days and nights per week with wheezing did not change over time in the placebo group (p < 0-24 and <0-41), but decreased from 4-6 to 3-4 days/ week and from 4-3 to 3-4 nights/week in the auranofin group (p < 0-0002). The changes were significantly different between the two groups (p < 0-02 and < 0-04). The severity of daytime and night time coughing (calculated as the cumulative daily score (0-4) during the week before each visit) did not change signifcantly over time in the auranofin group (from 5-1 to4-4duringtheday(p > 0-16)and4-0to 4-7 during the night (p > 0-06)). In the placebo group there was an increase from 4-8 to 9-3 during the day (p = 0-03) and from 6-8 to 10-9 during the night (p = 0-0002). The changes differed significantly between the two groups (p = 0 01 and 0-02). There were no significant changes over time in number of days per week with breathlessness or chest tightness.
Number of asthma attacks The number of asthma attacks decreased with time in both groups, with a slight trend in favour ofthe auranofin group (p = 0-04). There was no difference between the groups in the duration of the attacks (p = 0 56).
SUBJECTIVE ASSESSMENTS
The physicians' global assessment rated the condition of 1 1 of the 15 patients in the auranofin group as being improved, compared with three of the 13 patients in the placebo group (p = 0-02). ADVERSE 
REACTIONS
Apart from the two patients having auranofin who were withdrawn because of serious and resistant eczema, two further patients receiving auranofin developed transient mild eczema, with a good response to symptomatic treatment. They were able to continue auranofin in the normal dose. Nausea (three patients) and diarrhoea (one patient) occurred in patients taking auranofin and improved with reduction ofthe auranofin dose to 3 mg/day for two weeks. No significant changes in haematological or serum biochemical measurements or urine analysis were observed.
Discussion
The present study shows that oral gold (auranofin) reduces the daily requirement of oral corticosteroids and improves baseline FEV, in steroid dependent asthmatic patients. The auranofin group had fewer exacerbations requiring short courses of high dose steroids than the placebo group. There was an improvement ofasthma symptoms such as wheezing and cough, and the physicians' assessment was in favour of auranofin. These results suggest that auranofin may be helpful in patients who require oral corticosteroids. This is the first placebo controlled study to show that oral gold has steroid sparing activity in steroid dependent asthmatic patients. It confirms and extends the results of previous studies on the efficacy of gold injections (chrysotherapy) in asthma,'5 16 and of two uncontrolled studies on the steroid sparing effect of oral auranofin. '7 18 In contrast to the patients in these studies, most of our patients had asthma with non-allergic features. In addition, our patients had on average had asthma for longer and had lower baseline FEV, values.
We could not assess changes in airway responsiveness in these patients, because in most their FEV, was too low for them to have an inhalation provocation test. The severity and instability of the disease in our patients, who had fairly "brittle" asthma, caused some difficulty in the analysis. Short courses of high doses of oral prednisone were frequently indicated for exacerbations in addition to the maintenance doses. These short courses interfered with the linear relation between steroid dose and time, and might have influenced the results negatively. Despite this, both the number of exacerbations and the maintenance dosage of steroids were reduced in the auranofin group. There has been much concem about the side effects of long term systemic gold treatment. These include skin eruptions, stomatitis, proteinuria, microscopic haematuria, and haematological changes such as leucopenia and thrombocytopenia. '9 In the present study the incidence of side effects attributed to auranofin was rather low. Two patients developed moderately severe eczema, resistant to symptomatic treatment. Gastrointestinal side effects disappeared after reduction of the auranofin dosage. Although the adverse effects of auranofin were not compared directly with the adverse effects of oral prednisone over the same period in our study, our data suggest a favourable risk-benefit ratio of auranofin treatment, as has been reported in other studies.'8
The results of this study may have clinical implications. Our current understanding of the pathogenesis of asthma suggests that long term suppression of inflammation is the goal of asthma treatment. Inhaled anti-inflammatory drugs are usually effective, but in a few patients oral corticosteroids are necessary to control the disease. In view of the severity of the reported side effects of high dose steroid treatment, the minimal dose required to control asthma should be used. Auranofin 6 mg daily for 26 weeks has a steroid sparing effect. The relatively mild side effects of auranofin appeared to be acceptable to most patients; only exacerbation of constitutional eczema was a serious problem. Our study suggests that the administration of auranofin in some patients with severe steroid dependent asthma may be justified. Studying the effect of auranofin in patients requiring higher doses of oral steroids and comparing auranofin with oral prednisolone over a longer period would be worthwhile.
